Drug Discovery for Novel Coronavirus Infection (COVID-19)
Novel Coronavirus Infection (COVID-19)
What kind of disease is it?
COVID-19 is an infectious disease caused by a new type of coronavirus (SARS-CoV-2), which is transmitted through droplets produced when coughing, sneezing, or breathing. The symptoms of COVID-19 vary from person to person, and most of the infected people have mild to moderate symptoms that recover without hospitalization. However, there are severe cases that require long-term hospitalization and in some cases may even cause death. In addition, several mutant strains of the new coronavirus have been reported in various countries around the world, suggesting the possibility of increased infectivity and severe symptoms depending on the mutant strain.
What kind of treatment are we aiming to achieve with nucleic acids?
A small nucleic acid called "Bonac Nucleic Acid," suppresses the genes of new coronaviruses and aims to treat COVID-19 by inhibiting viral replication in infected cells by breaking down viral genes. By delivering the Bonac Nucleic Acid directly to the lungs via an inhaler, we aim to develop a therapeutic drug with fewer side effects. This drug directly targets the part of the viral gene that is difficult to mutate in the genetic sequence, which is shared by mutant strains of the new coronavirus and the virus that causes SARS (Severe Acute Respiratory Syndrome). Therefore, it may be effective against these viruses as well as newer coronavirus variants that may emerge in the future.
Detailed information on the new coronavirus drug being developed by Bonac
- We are currently developing this project through a collaboration with the national government, local governments, universities, and other research institutions. For further details, please refer to this page
- The adoption of the national project "CiCLE Project" was reported by KBC Kyushu Asahi Broadcasting.
Please visit the YouTube page for further information.
